Intellia Therapeutics, Inc. Forecasted to Post Q1 2023 Earnings of ($1.31) Per Share (NASDAQ:NTLA)
Intellia Therapeutics, Inc. Forecasted to Post Q1 2023 Earnings of ($1.31) Per Share (NASDAQ:NTLA)
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating) – SVB Leerink issued their Q1 2023 earnings estimates for shares of Intellia Therapeutics in a research note issued on Monday, January 23rd. SVB Leerink analyst M. Foroohar expects that the company will post earnings of ($1.31) per share for the quarter. SVB Leerink currently has a "Outperform" rating and a $84.00 target price on the stock. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($6.02) per share. SVB Leerink also issued estimates for Intellia Therapeutics' Q4 2023 earnings at ($1.26) EPS.
Intellia治療公司(納斯達克：NTLA-GET評級)-SVB Leerink在1月23日星期一發布的一份研究報告中發佈了他們對Intellia治療公司股票2023年第一季度收益的預期。SVB Leerink分析師M.Foroohar預計，該公司本季度每股收益將達到1.31美元。SVB Leerink目前對該股的評級為“跑贏大盤”，目標價為84.00美元。對Intellia治療公司目前全年收益的普遍估計為每股6.02美元。SVB Leerink還發布了對Intellia治療公司2023年第四季度每股收益的估計(1.26美元)。
Intellia Therapeutics (NASDAQ:NTLA – Get Rating) last posted its earnings results on Thursday, November 3rd. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.31) by ($0.18). The firm had revenue of $13.27 million for the quarter, compared to analysts' expectations of $13.60 million. Intellia Therapeutics had a negative net margin of 859.92% and a negative return on equity of 47.79%.
Intellia治療公司(納斯達克代碼：NTLA-GET評級)最近一次公佈收益結果是在11月3日星期四。該公司公佈了本季度每股收益(1.49美元)，低於普遍預期的(1.31美元)和(0.18美元)。該公司當季營收為1,327萬美元，高於分析師預期的1,360萬美元。Intellia治療公司的淨利潤率為負859.92%，淨資產回報率為負47.79%。
Intellia Therapeutics Price Performance
Intellia治療公司的價格表現
NASDAQ:NTLA opened at $38.53 on Tuesday. The firm has a market cap of $3.03 billion, a price-to-earnings ratio of -6.56 and a beta of 1.93. The company has a 50 day moving average price of $39.98 and a 200-day moving average price of $52.30. Intellia Therapeutics has a 1-year low of $32.44 and a 1-year high of $104.87.
納斯達克：NTLA週二開盤報38.53美元。該公司的市值為30.3億美元，市盈率為-6.56倍，貝塔係數為1.93。該公司的50日移動均線價格為39.98美元，200日移動均線價格為52.30美元。Intellia Treeutics的一年低點為32.44美元，一年高位為104.87美元。
Institutional Trading of Intellia Therapeutics
Intellia治療公司的制度性交易
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Eqis Capital Management Inc. raised its holdings in Intellia Therapeutics by 5.1% in the 3rd quarter. Eqis Capital Management Inc. now owns 4,345 shares of the company's stock valued at $243,000 after buying an additional 210 shares during the period. Xponance Inc. raised its holdings in Intellia Therapeutics by 5.2% in the 3rd quarter. Xponance Inc. now owns 4,250 shares of the company's stock valued at $238,000 after buying an additional 210 shares during the period. Steward Partners Investment Advisory LLC raised its holdings in Intellia Therapeutics by 10.2% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 2,368 shares of the company's stock valued at $123,000 after buying an additional 220 shares during the period. Amalgamated Bank raised its holdings in Intellia Therapeutics by 2.0% in the 3rd quarter. Amalgamated Bank now owns 11,352 shares of the company's stock valued at $635,000 after buying an additional 222 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Intellia Therapeutics by 1.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,777 shares of the company's stock valued at $883,000 after buying an additional 247 shares during the period. 85.61% of the stock is currently owned by hedge funds and other institutional investors.
幾家機構投資者和對衝基金最近買賣了該股的股票。Eqis資本管理公司在第三季度將其在Intellia Treateutics的持股增加了5.1%。Eqis Capital Management Inc.在此期間又購買了210股，現在擁有4,345股該公司股票，價值24.3萬美元。Xponance Inc.在第三季度將其在Intellia Treateutics的持股增加了5.2%。Xponance Inc.在此期間又購買了210股，目前持有該公司4,250股股票，價值23.8萬美元。Steward Partners Investment Consulting LLC在第二季度將其在Intellia Treateutics的持股增加了10.2%。Steward Partners Investment Consulting LLC現在擁有2368股該公司的股票，價值12.3萬美元，在此期間又購買了220股。合併銀行在第三季度增持了Intellia Treeutics 2.0%的股份。合併後的銀行現在擁有11,352股該公司股票，價值63.5萬美元，在此期間又購買了222股。最後，Zurcher Kantonalbank蘇黎世廣東銀行在第三季度增持了Intellia Treeutics 1.6%的股份。Zurcher Kantonalbank蘇黎世廣東銀行現在擁有15,777股該公司股票，價值883,000美元，在此期間又購買了247股。85.61%的股票目前由對衝基金和其他機構投資者持有。
Insider Transactions at Intellia Therapeutics
Intellia治療公司的內幕交易
In other news, CEO John M. Leonard sold 6,673 shares of Intellia Therapeutics stock in a transaction on Wednesday, January 4th. The stock was sold at an average price of $37.21, for a total transaction of $248,302.33. Following the transaction, the chief executive officer now owns 766,825 shares in the company, valued at approximately $28,533,558.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, EVP Laura Sepp-Lorenzino sold 2,508 shares of the business's stock in a transaction dated Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total value of $93,322.68. Following the sale, the executive vice president now directly owns 19,959 shares in the company, valued at approximately $742,674.39. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO John M. Leonard sold 6,673 shares of the business's stock in a transaction dated Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total transaction of $248,302.33. Following the completion of the sale, the chief executive officer now owns 766,825 shares in the company, valued at $28,533,558.25. The disclosure for this sale can be found here. Insiders have sold a total of 11,608 shares of company stock worth $431,934 in the last quarter. Company insiders own 2.60% of the company's stock.
其他消息方面，首席執行官約翰·M·倫納德在1月4日星期三的一筆交易中出售了6,673股Intellia治療公司的股票。該股以37.21美元的平均價格出售，總成交金額為248,302.33美元。交易完成後，這位首席執行官現在擁有該公司76.6825股，價值約28,533,558.25美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可以通過此超鏈接。在相關新聞中，執行副總裁Laura Sepp-Lorenzino在1月4日星期三的交易中出售了2,508股該公司的股票。這些股票的平均價格為37.21美元，總價值為93,322.68美元。出售後，執行副總裁總裁現在直接持有該公司19,959股股份，價值約742,674.39美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可以通過這個環節。此外，首席執行官約翰·M·倫納德在1月4日星期三的一筆交易中出售了6673股該公司的股票。這些股票的平均價格為37.21美元，總成交金額為248,302.33美元。出售完成後，首席執行官現在擁有該公司766,825股，價值28,533,558.25美元。關於這次銷售的披露可以找到這裏。上個季度，內部人士總共出售了11,608股公司股票，價值431,934美元。公司內部人士持有該公司2.60%的股份。
Intellia Therapeutics Company Profile
Intellia治療公司簡介
(Get Rating)
(獲取評級)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.
Intellia治療公司是一家基因組編輯公司，專注於治療學的開發。該公司的體內計劃包括NTLA-2001和NTLA-2002，NTLA-2001是治療轉甲狀腺素澱粉樣變性的第一階段臨牀試驗，NTLA-2002用於治療遺傳性血管水腫，以及其他以肝臟為重點的計劃，包括血友病A和血友病B、1型高草酸尿症和α-1抗胰蛋白酶缺乏症。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Intellia Therapeutics (NTLA)
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
- Can Coty Stock Emerge in 2023 With Upside
- Insiders Buy Archer Aviation, Is This Stock About To Take Off?
- Intuit Is About To Make a Move, But Which Way?
- 免費獲取StockNews.com關於Intellia治療(NTLA)的研究報告
- 高收益、高價值的Verizon陷入谷底
- 你應該用這隻反向ETF做空納斯達克100指數嗎？
- 科蒂股票能否在2023年出現上行
- 業內人士買入阿徹航空，這隻股票要起飛了嗎？
- Intuit即將採取行動，但走哪條路呢？
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Intellia治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Intellia治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。